EPHX2 and inflammatory bowel disease: Considering that sEH is overexpressed in human colitis and CRC (Zhang et al., 2013b), and that sEH inhibition blocks colonic inflammation and carcinogenesis (Wang et al., 2018b; Yang, 2018; Yang et al., 2018), sEH inhibition is a promising agent for the treatment of IBD.